Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

CUSIP: 48576U106

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 5 signals
Share change
-59,247,038
SEC-reported price per share
$3.74
Number of holders
2
Value change
-$55,318,808
Number of sells
86
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
22,658,403

Security key

48576U106

Report period

Q1 2025

Institutions

2

Top holders

2

Ownership snapshot

Top reported holders of KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
0/15
Latest evidence
31 Dec 2024
13F 3/4/5 Highest disclosed value: $5,174,430 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VANGUARD GROUP INC has the largest disclosed position value at $5.17M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VANGUARD GROUP INC's linked filing trail.
Disclosed position value Top 5
VANGUARD GROUP INC $5.17M
ADAGE CAPITAL PARTNERS GP, L.L.C. $4.27M
Palo Alto Investors LP $3.32M
BlackRock, Inc. $2.55M
MORGAN STANLEY $2.38M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$5,174,430
7,654,482 shares
— 31 Dec 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$4,274,109
6,319,842 shares
— 31 Dec 2024
Palo Alto Investors LP
13F
Company
13F
—
denominator unverified
$3,318,605
4,907,001 shares
— 31 Dec 2024
BlackRock, Inc.
13F
Company
13F
—
denominator unverified
$2,548,889
3,768,875 shares
— 31 Dec 2024
MORGAN STANLEY
13F
Company
13F
—
denominator unverified
$2,375,969
3,513,188 shares
— 31 Dec 2024
CITADEL ADVISORS LLC
13F
Company
13F
—
denominator unverified
$2,099,011
3,103,669 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
2
Shares
352,017
Rows available
2
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q2 2026 Across Filers

Q2 2026 holders
1
Q1 2025 holders
2
Holder diff
1
Investor Q2 2026 Shares Q1 2025 Shares Share Diff Share Chg % Q2 2026 value Q1 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .